EGFR and non-small cell lung carcinoma: Among patients who underwent PET staging, maximum standardized uptake values were significantly higher among patients with wildtype EGFR NSCLC compared with those with EGFR-positive NSCLC (median [range], 9.0 [1.3-32] vs 4.8 [1-61]; P < .001).